RxDoctor Payments Data

Phuong Trinh, MD

Family Medicine · Philadelphia, PANPI 1093754376

Payments from drug & device makers

$1,543in general payments, 2019–2025

Across 72 payments — averaging $21.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kowa Pharmaceuticals America, Inc.$491
  • Gilead$450
  • Amarin Pharma, Inc.$328
  • Merck$100
  • GSK$57
  • Amgen$50
  • plus $67 from 3 others

What the payments were for

  • Food & beverage$1,52399%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,543 in reported general payments places this provider in the 75th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$23,073
Medicare patients
84
Services billed
257

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate197$168,052
JardianceEmpagliflozin161$132,588
VascepaIcosapent Ethyl71$43,791
TrulicityDulaglutide22$22,939
Fluticasone-SalmeterolFluticasone Propion/Salmeterol55$16,559
Omega-3 Acid Ethyl Esters136$12,842
EliquisApixaban12$8,419
Breo ElliptaFluticasone/Vilanterol19$8,103
Rosuvastatin Calcium389$7,557
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog22$6,654
TradjentaLinagliptin12$6,115
Albuterol Sulfate HfaAlbuterol Sulfate105$5,148
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$5,033
Icosapent Ethyl19$4,190
Diclofenac Sodium107$3,892

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$100$168,052197 claims
GSKBreo Ellipta, Anoro Ellipta$57$13,13630 claims
AstraZenecaSymbicort$20$2,49112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →